⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 15 in last 7 days 🍎 Food: 1 in last 7 days 🧸 Products: 52 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 4 hours ago ⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 15 in last 7 days 🍎 Food: 1 in last 7 days 🧸 Products: 52 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 4 hours ago
🛡️ EUSW
💊 Medicines 🍎 Food 🧸 Products 🔎 Search
📊 Data
🏷 Brands 🌍 Countries ℹ️ About ✉ Unsubscribe
🇬🇧
🇬🇧 English 🇳🇱 Nederlands 🇫🇷 Français 🇩🇪 Deutsch 🇪🇸 Español 🇮🇹 Italiano 🇵🇹 Português 🇵🇱 Polski 🇸🇪 Svenska 🇷🇴 Română 🇨🇿 Čeština 🇫🇮 Suomi 🇩🇰 Dansk
💊 Medicine EU November 7, 2023

Hycamtin

📷 Wikipedia: Topotecan · Source
Hycamtin
📷 Wikipedia: Topotecan · Source
INN
topotecan
Forms
Capsule, hard
Strengths
0.5 mg;1 mg
Area
Ovarian Neoplasms;Uterine Cervical Neoplasms;Small Cell Lung Carcinoma
Alternatives
Yes
🗄
Archived (older alert)
This alert was reported 994 days ago and has been moved from our active feed to the archive. The original safety information still applies — we have no confirmation from the issuing agency that the product is safe again. Refer to the official notice for the current status.
📈 Timeline
69 days in total
May 20, 2026 July 28, 2026
Daily snapshot data starts accumulating once the scheduler runs — for now this is interpolated from the agency's first/last dates.

What is this? Hycamtin is a medicine with the active substance topotecan. It comes as hard capsules. It is used to treat certain cancers.

What's happening? There is a shortage of Hycamtin capsules in the EU. Other similar medicines are available.

Does this affect me? If you take Hycamtin, your doctor may switch you to another medicine.

What should I do? Talk to your doctor or pharmacist before changing anything.

🤖 This plain-language summary is automatically generated from the official agency notice using AI. It is for general information only — not medical advice. For decisions about your health, always consult a pharmacist or doctor and read the official source linked below.

🔬 Medical / technical details (for professionals)
Active substance(s)
topotecan
Brand(s) / product name(s)
Hycamtin
Agency-published detail

INN: topotecan · Forms: Capsule, hard · Strengths: 0.5 mg;1 mg · Area: Ovarian Neoplasms;Uterine Cervical Neoplasms;Small Cell Lung Carcinoma · Alternatives: Yes

First published
November 7, 2023
Last refreshed by us
2 months ago
Severity (as classified)
Medium
Official source
http://www.ema.europa.eu/en/medicines/human/shortages/hycamtin

All information on this page comes from the official agency notice. We translate and summarise it; we don't add or edit facts.

❓ Frequently asked questions

▸ What is this medicine shortage alert about?
Hycamtin. INN: topotecan · Forms: Capsule, hard · Strengths: 0.5 mg;1 mg · Area: Ovarian Neoplasms;Uterine Cervical Neoplasms;Small Cell Lung Carcinoma · Alternatives: Yes
▸ When was this alert issued?
This alert was issued on November 7, 2023 by EMA (European Medicines Agency).
▸ Which countries are affected?
The alert applies to the entire EU.
▸ How serious is this alert?
Medium risk. A medium risk means harm is possible under certain conditions. Read the notice and act on the recommended steps.
▸ What should I do?
If you take this medicine, contact your pharmacist or prescribing doctor. They can advise on alternative products or substitutes. Do not stop taking prescription medicine without medical advice.
▸ Where can I find the official notice?
The full official notice is published on www.ema.europa.eu.

💬 Discussion

Share your experience or ask a question. Real names and email are optional but moderation friendly.

No comments yet — be the first.

We email a confirmation link. Your address stays private.

⚠️ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.